Mesa Laboratories, Inc. (MLAB) To Go Ex-Dividend on February 28th

Mesa Laboratories, Inc. (NASDAQ:MLAB) announced a quarterly dividend on Tuesday, January 7th,Wall Street Journal reports. Shareholders of record on Friday, February 28th will be given a dividend of 0.16 per share by the medical instruments supplier on Monday, March 17th. This represents a $0.64 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date is Friday, February 28th.

Mesa Laboratories has a payout ratio of 5.9% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Mesa Laboratories to earn $7.82 per share next year, which means the company should continue to be able to cover its $0.64 annual dividend with an expected future payout ratio of 8.2%.

Mesa Laboratories Stock Up 2.2 %

Mesa Laboratories stock opened at $142.03 on Thursday. Mesa Laboratories has a one year low of $83.68 and a one year high of $147.34. The stock has a fifty day moving average of $122.69 and a 200 day moving average of $119.60. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.51 and a current ratio of 0.70. The stock has a market cap of $771.36 million, a PE ratio of -3.12 and a beta of 0.82.

Insider Buying and Selling at Mesa Laboratories

In other news, CEO Gary M. Owens sold 2,518 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $113.62, for a total transaction of $286,095.16. Following the sale, the chief executive officer now directly owns 45,888 shares of the company’s stock, valued at $5,213,794.56. This represents a 5.20 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. StockNews.com downgraded Mesa Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, November 13th. Evercore ISI lifted their price target on shares of Mesa Laboratories from $120.00 to $160.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.